NCT04319341View on ClinicalTrials.gov

Obstetric Antiphospholipid Antibody Syndrome : Contribution of the Evaluation of ADAMTS13 Made at the Diagnosis of Pregnancy on Evaluation the Risk of Pre-eclampsia

CompletedOBSERVATIONAL
Enrollment

513

Participants

Timeline

Start Date

April 1, 2020

Primary Completion Date

December 30, 2020

Study Completion Date

December 30, 2020

Conditions
Antiphospholipid Antibody Syndrome in Pregnancy
Interventions
OTHER

To study the prognostic value on the occurrence of pre-eclampsia, ADAMTS13 (ADAMTS13 protein and autoantibodies) in patients diagnosed with oAPS

ADAMTS13 activity, ADAMS13 antigen and anti-ADAMTS13 autoantibodies: U/ml.

Trial Locations (1)

30029

CHU de Nîmes - Hôpital Universitaire Carémea, Nîmes

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nīmes

OTHER

NCT04319341 - Obstetric Antiphospholipid Antibody Syndrome : Contribution of the Evaluation of ADAMTS13 Made at the Diagnosis of Pregnancy on Evaluation the Risk of Pre-eclampsia | Biotech Hunter | Biotech Hunter